Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo Refoios Camejo

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 4, 2013
Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPDRodrigo Refoios Camejo, Rodrigo Refoios Camejo, Clare McGrath, et al.
Health Policy (Amsterdam, Netherlands)|September 25, 2010
A dynamic perspective on pharmaceutical competition, drug development and cost effectivenessRodrigo Refoios Camejo, Clare McGrath, Ron Herings
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Cost-Effectiveness and Dynamic Efficiency: Does the Solution Lie Within?Rodrigo Refoios Camejo, Marisa Miraldo, Frans Rutten
Pharmacoeconomics|April 11, 2013
The determinants of cost-effectiveness potential: an historical perspective on lipid-lowering therapiesRodrigo Refoios Camejo, Clare McGrath, Marisa Miraldo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2013
Assessing the determinants of the potential for cost-effectiveness over time: the empirical case of COPDRodrigo Refoios Camejo, Clare McGrath, Ron Herings, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 22, 2012
Antihypertensive drugs: a perspective on pharmaceutical price erosion and its impact on cost-effectivenessRodrigo Refoios Camejo, Clare McGrath, Ron Herings, et al.
Advances in Therapy|April 10, 2019
Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-AnalysisHongxin Zhao, Yi Ning, James Cooper, et al.
Kidney Medicine|October 22, 2020
Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling EraBorut Cizman, Helen T Smith, Rodrigo Refoios Camejo, et al.
Plos One|September 5, 2014
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysisDipen A Patel, Sonya J Snedecor, Wing Yu Tang, et al.
Clinical Kidney Journal|January 22, 2024
Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populationsAlfred Sackeyfio, Renato D Lopes, Csaba P Kovesdy, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 4, 2013
Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPDRodrigo Refoios Camejo, Rodrigo Refoios Camejo, Clare McGrath, et al.
Health Policy (Amsterdam, Netherlands)|September 25, 2010
A dynamic perspective on pharmaceutical competition, drug development and cost effectivenessRodrigo Refoios Camejo, Clare McGrath, Ron Herings
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Cost-Effectiveness and Dynamic Efficiency: Does the Solution Lie Within?Rodrigo Refoios Camejo, Marisa Miraldo, Frans Rutten
Pharmacoeconomics|April 11, 2013
The determinants of cost-effectiveness potential: an historical perspective on lipid-lowering therapiesRodrigo Refoios Camejo, Clare McGrath, Marisa Miraldo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2013
Assessing the determinants of the potential for cost-effectiveness over time: the empirical case of COPDRodrigo Refoios Camejo, Clare McGrath, Ron Herings, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 22, 2012
Antihypertensive drugs: a perspective on pharmaceutical price erosion and its impact on cost-effectivenessRodrigo Refoios Camejo, Clare McGrath, Ron Herings, et al.
Advances in Therapy|April 10, 2019
Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-AnalysisHongxin Zhao, Yi Ning, James Cooper, et al.
Kidney Medicine|October 22, 2020
Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling EraBorut Cizman, Helen T Smith, Rodrigo Refoios Camejo, et al.
Plos One|September 5, 2014
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysisDipen A Patel, Sonya J Snedecor, Wing Yu Tang, et al.
Clinical Kidney Journal|January 22, 2024
Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populationsAlfred Sackeyfio, Renato D Lopes, Csaba P Kovesdy, et al.
Pageof 2